| Literature DB >> 30097052 |
Premkumari Kumarathasan1,2, Renaud Vincent3,4, Erica Blais5, Agnieszka Bielecki5, Josée Guénette5, Alain Filiatreault5, Orly Brion5, Sabit Cakmak5, Errol M Thomson5, Robin Shutt5, Lisa Marie Kauri5, Mamun Mahmud5, Ling Liu5, Robert Dales5.
Abstract
BACKGROUND: There is a paucity of mechanistic information that is central to the understanding of the adverse health effects of source emission exposures. To identify source emission-related effects, blood and saliva samples from healthy volunteers who spent five days near a steel plant (Bayview site, with and without a mask that filtered many criteria pollutants) and at a well-removed College site were tested for oxidative stress, inflammation and endothelial dysfunction markers.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30097052 PMCID: PMC6086065 DOI: 10.1186/s12989-018-0270-4
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Sequence of exposure patterns followed in this study for all 4 cohorts
| 1st Exposure | Washout | 2nd Exposure | Washout | 3rd Exposure | |
|---|---|---|---|---|---|
| Sequence | (5 days) | Period (days) | (5 days) | Period (days) | (5 days) |
| 1 | A | 9 | B | 9 | C |
| 2 | B | 9 | C | 9 | A |
| 3 | C | 9 | A | 9 | B |
| 4 | A | 9 | C | 9 | B |
| 5 | B | 9 | A | 9 | C |
| 6 | C | 9 | B | 9 | A |
Note: Cohorts 1–4 were spaced by time and the entire exposure took place from May–August 2010
A Bayview Mask, B Bayview Ambient (without mask) and C College
General characteristics of the study subjects
| Participant Characteristics | Median |
|---|---|
| Age (year) (5th- 95th percentile) | 23.0 (18–34) |
| Sex, female/male (number) | 28/24 |
| Body Mass Index (kg/m2) (5th- 95th percentile) | 25.3 (19.6–35.5) |
| Ethnicity, Caucasian/other (number) | 44/8 |
| Baseline Systolic Blood Pressure (mmHg) (5th - 95thpercentile) | 106.5 (92.5–128.5) |
| Baseline Diastolic Blood Pressure (mmHg) (5th- 95th percentile) | 68.0 (57.9–85.9) |
| Baseline Heart Rate (bpm) (5th- 95th percentile) | 73.2 (58.4–92) |
Daily average air pollutant levels on Fridays for the two study sites (Bayview and College sites)
| Pollutant | College Site (Fridays) | Bayview Site (Fridays) |
|---|---|---|
| CO (IQR 0.4 ppm) | 0.44 (0.43, 0.45) | 1.07 (0.95, 1.19) |
| NO (IQR 6.7 ppb) | 1.52 (1.44, 1.60) | 6.93 (6.61, 7.24) |
| NO2 (IQR 6.6 ppb) | 4.39 (4.19, 4.58) | 6.78 (6.49, 7.07) |
| NOx (IQR 13.2 ppb) | 5.90 (5.65, 6.15) | 13.52 (12.98, 14.07) |
| O3 (IQR 9.2 ppb) | 32.81 (32.19, 33.44) | 29.91 (29.38, 30.44) |
| PM2.5 (IQR 11.0 μg/m3) | 11.48 (10.97, 11.99) | 12.95 (12.41, 13.48) |
| SO2 (IQR 14.8 ppb) | 1.56 (1.39, 1.73) | 8.13 (7.28, 8.98) |
| UFP (IQR 32161 particle/cm3) | 6523 (6080, 6966) | 14,830 (13,604, 16,057) |
Comparison between biomarker levels after the Bayview site (“without”mask) vs College site exposures
| Biomarker | Bayview (“without” mask) vs College site |
|---|---|
| A2M | 0.887 (0.755, 1.043)+a |
| Adiponectin | 1.184 (1.013, 1.385)*b |
| AGP | 0.749 (0.590, 0.952)*a |
| CRP | 1.410 (0.887, 2.240)+a |
| Haptoglobin | 0.852 (0.734, 0.989)*a |
| IL-1β | 1.050 (0.999, 1.104)+b |
| IL-4 | 1.317 (1.021, 1.699)*a |
| IL-6 | 1.143 (1.002, 1.305)*c |
| PF4 | 0.847 (0.709, 1.011)+a |
| Plasma ET-1(1–21) | 1.497 (0.957, 2.340)+a |
| Plasma ET-3 | 1.330 (1.037, 1.705)*a |
| Saliva BET-1 | 1.302 (1.034, 1.641)*c |
| Saliva ET-1(1–21) | 1.167 (1.031, 1.320)*b |
| Saliva ET-3 | 1.114 (0.979, 1.267)+b |
| TNF-α | 1.076 (1.005, 1.151)*c |
| vWF | 0.552 (0.349, 0.875)*a |
*p < 0.05; +p < 0.1(not significant, trend only)
aCovariates: Treatment period, carry over, age, sex, BMI, atmospheric pressure, temperature, relative humidity
bCovariates: Treatment period, carry over
cCovariates: Treatment period, carry over, age, sex, BMI
Comparison of target biomarker levels after the Bayview site (“with” mask) vs College site exposures
| Biomarker | Bayview (“with” mask) vs College site |
|---|---|
| Adiponectin | 1.133 (0.967, 1.327)+b |
| AGP | 0.744 (0.584, 0.949)*a |
| Haptoglobin | 0.814 (0.700, 0.947)*a |
| IFNγ | 1.134 (0.994, 1.294)+b |
| IL-2 | 0.782 (0.640, 0.956)*a |
| IL-4 | 1.229 (0.950, 1.590)+a |
| IL-8 | 1.049 (0.986, 1.117)+b |
| PF4 | 0.836 (0.698, 1.001)+a |
| Plasma ET-1(1–21) | 1.443 (0.917, 2.269)+a |
| Plasma ET-3 | 1.272 (0.989, 1.636)+a |
| Saliva BET-1 | 1.367 (1.085, 1.723)*c |
| Saliva ET-1(1–21) | 1.165 (1.030, 1.318)*b |
| Saliva ET-1(1–31) | 1.132 (0.974, 1.314)+c |
| SAP | 0.770 (0.543, 1.092)+a |
| TNF-α | 1.075 (1.004, 1.151)*c |
| vWF | 0.622 (0.390, 0.991)*a |
*p < 0.05; +p < 0.1(not significant, trend only)
aCovariates: Treatment period, carry over, age, sex, BMI, atmospheric pressure, temperature, relative humidity
bCovariates: Treatment period, carry over
cCovariates: Treatment period, carry over, age, sex, BMI
Comparison of target biomarker levels after the Bayview site (“without” mask) vs Bayview site (“with” mask) exposures
| Comparison | IL-1β | IL-2 | Plasma BET-1 |
|---|---|---|---|
| Bayview Ambient vs | 1.061 (1.012, 1.112)* | 1.153 (1.027, 1.294)* | 1.135 (0.959, 1.344)+ |
*p < 0.05; +p < 0.1(not significant, trend only)
Note: Covariates: Treatment period, carry over, age, sex, BMI, atmospheric pressure, temperature, relative humidity
Relative change in target biomarker levels associated with IQR changes in air pollutant levels
| Pollutant | Biomarker | Ratio (95%CI) |
|---|---|---|
| CO | IL-12 | 1.077 (1.018, 1.139)* |
| IL-13 | 1.046 (1.009, 1.086)* | |
| IL-5 | 1.022 (0.998, 1.047)+ | |
| IL-6 | 1.042 (1.009, 1.077)* | |
| IL-7 | 1.043 (1.007, 1.080)* | |
| IL-8 | 1.016 (1.001, 1.032)* | |
| L Selectin | 0.966 (0.934, 1.000)* | |
| ET 1–21 (saliva) | 0.966 (0.933, 1.000)* | |
| ET 1–31 (saliva) | 0.962 (0.920, 1.007)+ | |
| ET 3 (saliva) | 1.011 (0.975, 1.047)+ | |
| NO | GMCSF | 0.910 (0.818, 1.012)+ |
| IL-4 | 0.859 (0.718, 1.027)+ | |
| IL-8 | 0.906 (0.845, 0.972)* | |
| NO2 | ET 1–21 (saliva) | 1.090 (0.904, 1.314)+ |
| NOX | IL-8 | 0.915 (0.847, 0.989)* |
| O3 | Adipsin | 0.669 (0.433, 1.034)+ |
| GMCSF | 1.170 (0.979, 1.398)+ | |
| IL-2 | 1.476 (1.120, 1.945)* | |
| L Selectin | 0.794 (0.630, 1.000)+ | |
| Big ET-1 (plasma) | 1.417 (1.024, 1.962)* | |
| Big ET-1 (saliva) | 0.616 (0.363, 1.046)+ | |
| ET 1–21 (saliva) | 0.776 (0.609, 0.988)* | |
| SAP | 0.672 (0.445, 1.013)+ | |
| TNF-α | 1.143 (1.006, 1.299)* | |
| vWF | 0.562 (0.328, 0.963)* | |
| SO2 | Haptoglobin | 1.080 (0.988, 1.182)+ |
| PF4 | 0.914 (0.829, 1.007)+ | |
| ET 1–21 (plasma) | 1.401 (1.056, 1.858)* | |
| vWF | 1.265 (0.953, 1.679)+ | |
| UFP | A2M | 0.543 (0.348, 0.848)* |
| Adipsin | 0.244 (0.095, 0.627)* | |
| AGP | 0.362 (0.209, 0.626)* | |
| Fibrinogen | 0.504 (0.309, 0.823)* | |
| Haptoglobin | 0.548 (0.359, 0.837)* | |
| L Selectin | 0.684 (0.495, 0.947)* | |
| PF4 | 0.464 (0.287, 0.750)* | |
| ET 1–21 (plasma) | 4.405 (1.143, 16.973)* | |
| PM2.5 | IL-4 | 0.837 (0.700, 1.000)+ |
| ET 1–21 (saliva) | 1.166 (1.001, 1.344)* | |
| ET 1–31 (saliva) | 1.195 (0.998, 1.430)+ | |
| vWF | 1.373 (0.985, 1.912)+ |
*p < 0.05; +p < 0.1(not significant, trend only)
Covariates: Treatment period, carry over, Age, sex, BMI, atmospheric pressure, temperature and relative humidity
Change in physiological endpoints by exposure
| Site Comparison | Physiological endpoint | ||
|---|---|---|---|
| Systolic BP (mmHg) | Diastolic (mmHg) | Heart Rate (bpm) | |
| Bayview “with” mask vs College site | −0.7439 (− 3.4666, 1.9789) | −0.5652 (− 2.7252, 1.5947) | 3.5312 (1.1294, 5.9330)* |
| Bayview “with” mask vs Bayview “without” mask | −1.2172 (− 3.8714, 1.4370) | − 0.6673 (− 2.7715, 1.4368) | 2.3532 (0.0150, 4.6913)* |
| College site vs Bayview “without” mask | − 0.4733 (− 3.1738, 2.2272) | −0.1021 (− 2.2438, 2.0396) | − 1.1780 (− 3.5589, 1.2029)* |
*p < 0.05
Covariates: Carry over, age, sex and BMI, sequential order of treatments
IQR changes in air pollutants and associated changes in physiological endpoints
| Pollutant | Physiological endpoints | ||
|---|---|---|---|
| Systolic BP | Diastolic BP | Heart Rate | |
| CO (ppm) | −0.07 (− 0.34, 0.20) | −0.22 (− 0.45, − 0.002)* | 0.13 (− 0.11, 0.36) |
| NO (ppb) | 0.46 (−0.87, 1.79) | 0.62 (−0.48, 1.72) | 1.75 (0.47, 3.03)* |
| NO2 (ppb) | − 0.74 (− 2.73, 1.24) | − 1.64 (− 3.31, 0.030)+ | 0.60 (− 0.84, 2.03) |
| NOx (ppb) | 0.31 (− 1.64, 2.25) | −1.64 (− 3.54, 0.25)+ | 1.89 (− 0.002, 3.78)+ |
| O3 (ppb) | − 1.48 (− 2.76, − 0.20)* | − 1.82 (− 2.85, − 0.78)* | 1.62 (0.49, 2.75)* |
| PM2.5 (ug/m3) | − 0.97) (−2.31, 0.38) | −1.97 (− 3.04, − 0.89)* | 1.52 (0.35, 2.7)* |
| SO2 (ppb) | − 0.15 (− 0.70, 1.01) | −0.26 (− 0.96, 0.45) | 0.22 (− 0.53, 0.98) |
| UFP (particle/cm3) | 6.25 (2.79, 9.71)* | − 4.67 (− 9.56, 0.22)+ | 1.35 (0.29, 2.42)* |
*p < 0.05; +p < 0.1(not significant, trend only)
Covariates: Carry over, age, sex and BMI, sequential order of treatments
Change in physiological endpoints associated with IQR changes in target biomarkers
| Biomarker | Physiological Parameters | ||
|---|---|---|---|
| Systolic BP (mmHg) | Diastolic BP (mmHg) | Heart Rate (bpm) | |
| Adipsin | −1.94 (− 3.62, −0.26)*a | 0.38 (− 0.81, 1.04)a | − 0.06 (− 1.62, 1.51)a |
| CRP | 0.40 (− 0.28, 1.08)a | 0.24 (− 0.27, 0.76)a | 1.13 (0.56, 1.69)*b |
| IL-10 | − 0.01 (− 0.85, 0.82)a | − 0.15 (− 0.77, 0.47)a | − 0.61 (− 1.33, 0.10)+a |
| IL-12 | − 0.07 (− 0.27, 0.14)a | − 0.05 (− 0.20, 0.10)a | − 0.25 (− 0.42, − 0.08)*a |
| IL-6 | 0.08 (− 1.00, 1.15)a | − 0.09 (− 0.09, 0.73)a | − 1.09 (− 2.01, − 0.17)*a |
| IL-7 | − 0.14 (− 1.05, 0.76)a | − 0.20 (− 0.88, 0.47)a | − 0.68 (− 1.45, 0.10)+a |
| PF4 | − 1.57 (− 2.95, − 0.19)*a | 0.19 (− 0.87, 1.26)a | 0.03 (− 1.17, 1.24)a |
| Plasma BET-1 | 1.41 (−0.59, 3.41)a | − 1.22 (− 2.65, 0.20)*c | −0.44 (− 2.17, 1.30)a |
| Saliva BET-1 | 1.82 (0.64, 3.00)*a | 1.11 (0.08, 2.14)*a | − 0.02 (− 1.21, 1.16)a |
| Saliva ET-1(1–21) | 1.78 (−0.25, 3.80)+a | 0.66 (− 0.94, 2.25)a | − 1.01 (− 2.81, 0.80)a |
| vWF | − 0.35 (− 1.25, 0.55)a | 0.77 (0.08, 1.45)*c | −0.39 (− 1.22, 0.43)+a |
*p < 0.05; +p < 0.1(not significant, trend only)
aCovariates: Treatment period, and carry over
bCovariates:Treatment period, carry over, age, sex and BMI
cCovariates: Treatment period, carry over, age, sex and BMI, atmospheric pressure, temperature, and relative humidity
Fig. 1Heat map and hierarchical clustering analysis results. Bayview A – Bayview Ambient (“without” mask); Bayview M- “with” mask; Biomarker levels are expressed as fold changes with respect the subject’s average biomarker level through the entire exposure period (Red-upregulation; Green-down-regulation)
Fig. 2Protein networks from IPA analyses. Biomarker levels at the Bayview site are expressed as fold changes with respect to the College site levels. a Network 1 (“with” mask) b Network 2 (“without” mask). (Red- upregulation; Green- down-regulation)